114379-92-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-(methyl-d3)phenyl)ethan-1-one is used as a key intermediate in the preparation of crystalline forms of substituted Imidazopyrazinecarboxamides. These compounds serve as Phosphoinositide 3-kinase (PI3K) inhibitors, which play a crucial role in the regulation of cellular processes such as cell growth, survival, and metabolism. The deuterated version of 1-(4-(methyl-d3)phenyl)ethan-1-one is particularly useful in the development of more effective and targeted therapies for various diseases, including cancer.
Used in Cosmetics and Perfumery Industry:
1-(4-(methyl-d3)phenyl)ethan-1-one is used as a methylated acetophenone in cosmetics and perfumery. Its unique scent profile and stability make it a valuable ingredient in the formulation of fragrances and other cosmetic products. The presence of the deuterium atom in 1-(4-(methyl-d3)phenyl)ethan-1-one may also provide additional benefits, such as enhanced stability and longevity of the fragrance.
Used in Polymer Industry:
1-(4-(methyl-d3)phenyl)ethan-1-one is used as a catalyst in the photopolymerization of Methyl methacrylate. The presence of the 4''-Methylacetophenone has been shown to accelerate the photopolymerization process, leading to faster curing times and improved material properties. This makes it a valuable component in the production of various polymer-based materials, such as coatings, adhesives, and plastics.

Upstream product

• 1124-18-1 toluene-d3 
• 108-24-7 acetic anhydride 
• 13329-40-3 4-Iodoacetophenone 
• 7575-93-1 methyl-d3 4-methylbenzenesulfonate 
• 865-50-9 iodomethane-d3 
• 149104-90-5 4-acetylphenylboronic acid 
• 98-07-7 Benzotrichlorid 

Downstream Products

• 108757-37-5 acetic acid-(4-trideuteriomethyl-anilide) 
• 114618-96-1 acetic acid-(4-trideuteriomethyl-phenyl ester) 

Relevant academic research and scientific papers

CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR

The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.

CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Nickel and Nucleophilic Cobalt-Catalyzed Trideuteriomethylation of Aryl Halides Using Trideuteriomethyl p-Toluenesulfonate

Herein, a novel approach for the trideuteriomethylation of aryl halides using nickel and nucleophilic cobalt catalysts and the readily available trideuteriomethyl p-toluenesulfonate (CD3OTs) is described. This method provides access to a wide r

PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS

The present disclosure is directed to modulators of GABAA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of sleep disorders and/or for providing a patient in need with a hypnotic, anxiolytic or anti-convulsive effect are described.